Author Archives for Adeline Chauvigné

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article

Rédigé par Adeline Chauvigné, le 2021-05-26

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article

Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Rédigé par Adeline Chauvigné, le 2021-05-25

Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

New member | Attonuclei

ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article

Rédigé par Adeline Chauvigné, le 2021-06-02

New member | Attonuclei

ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article

Rédigé par Adeline Chauvigné, le 2021-05-26

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article

Valneva Announces Closing of $107.6 million Global Offering

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Rédigé par Adeline Chauvigné, le 2021-05-11

Valneva Announces Closing of $107.6 million Global Offering

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Rédigé par Adeline Chauvigné, le 2021-05-07

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article

Clinical Study demonstrates promising results for Investigative ALS Treatment; InFlectis BioScience is planning phase 2 trial of Next-Generation Therapy

A new study shows indications that Amyotrophic Lateral Sclerosis (ALS) may be treated with small molecules targeting the Integrated Stress... View Article

Rédigé par Adeline Chauvigné, le 2021-06-02

Clinical Study demonstrates promising results for Investigative ALS Treatment; InFlectis BioScience is planning phase 2 trial of Next-Generation Therapy

A new study shows indications that Amyotrophic Lateral Sclerosis (ALS) may be treated with small molecules targeting the Integrated Stress... View Article

CLEAN BIOLOGICS SAS ACQUIRES BIODEXTRIS INC.

The transaction enables the ArchiMed-backed Clean Biologics group to establish North American presence and expand their activities with Biodextris’ complementary... View Article

Rédigé par Adeline Chauvigné, le 2021-06-02

CLEAN BIOLOGICS SAS ACQUIRES BIODEXTRIS INC.

The transaction enables the ArchiMed-backed Clean Biologics group to establish North American presence and expand their activities with Biodextris’ complementary... View Article

XENOTHERA And Its Partner Excelya Announce the Recruitment of the First Patient in The EUROXAV Clinical Trial of its COVID Treatment XAV-19

#COVID19 #ClinicalTrial #Treatment #PolyclonalAntibodies The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory... View Article

Rédigé par Adeline Chauvigné, le 2021-05-25

XENOTHERA And Its Partner Excelya Announce the Recruitment of the First Patient in The EUROXAV Clinical Trial of its COVID Treatment XAV-19

#COVID19 #ClinicalTrial #Treatment #PolyclonalAntibodies The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory... View Article

WAVEIMPLANT winner of the Tech Tour France 2021

WAVEIMPLANT, a young innovative company developing ImplantUS, a medical device for measuring the stability of dental implants and securing associated... View Article

Rédigé par Adeline Chauvigné, le 2021-05-26

WAVEIMPLANT winner of the Tech Tour France 2021

WAVEIMPLANT, a young innovative company developing ImplantUS, a medical device for measuring the stability of dental implants and securing associated... View Article